journal article·2009-09

Matrix therapy in regenerative medicine, a new approach to chronic wound healing

V. Barbier‐Chassefière, S. Garcia‐Filipe, X. L. Yue, M. E. Kerros, E. Petit, P. Kern, J. L. Saffar, D. Papy‐Garcia, J. P. Caruelle, D. Barritault

Publisher page

Abstract

Abstract Nonhealing wounds remain a major health problem whose treatment is challenging and costly. Treatments based on cells or growth factors are still not very effective. We developed an entirely novel strategy consisting in treatment of the wound‐tissue matrix with biopolymers engineered to mimic heparan sulfates called OTR4120. This compound was dextran polymer with sulfated and carboxymethyl groupments. After binding to matrix proteins, the heparan‐sulfate‐mimicking polymer protects the microenvironment, maintaining the normal production of signals and growth factors needed for healing to occur. Here, we show that a specific biopolymer accelerates ulcer closure and improves re‐epithelialization and dermal‐matrix‐component remodeling. OTR4120 treatment was associated with faster maturation of epidermal structures, most notably regarding the number of epithelial‐cell layers, and with an appearance that more closely resembled normal skin. Treatment had also a main effect on collagen I and III expression. Necrotic skin ulcers induced in mice with doxorubicin recovered normal collagen levels and organization, with no evidence of fibrosis. Thus, appropriate polymer‐based matrix therapy is a valid and simple alternative to regenerative medicine. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Wound Healing and Treatments · Tendon Structure and Treatment · Surgical Sutures and Adhesives

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. 10.1046/j.1087-0024.2000.00014.x10.1046/j.1087-0024.2000.00014.x ↗
2. 10.1016/S0140-6736(03)13169-810.1016/S0140-6736(03)13169-8 ↗
3. 10.1097/00006534-199802000-0001610.1097/00006534-199802000-00016 ↗
4. Wound fluids and the pathogenesis of chronic wounds
5. 10.1097/00005373-199607000-0002910.1097/00005373-199607000-00029 ↗
6. 10.3109/0284431940907118610.3109/02844319409071186 ↗
7. 10.1042/BJ2003123010.1042/BJ20031230 ↗
8. 10.1074/jbc.R00000820010.1074/jbc.R000008200 ↗
9. 10.1146/annurev.biochem.67.1.60910.1146/annurev.biochem.67.1.609 ↗
10. 10.1021/ma048485p10.1021/ma048485p ↗
11. 10.1016/S0002-9440(10)63161-610.1016/S0002-9440(10)63161-6 ↗
12. 10.1136/gut.53.1.8510.1136/gut.53.1.85 ↗
13. 10.1159/00001665110.1159/000016651 ↗
14. 10.1096/fj.02-0708com10.1096/fj.02-0708com ↗
15. Experimental skin necrosis produced by adriamycin
16. 10.1007/BF0100277210.1007/BF01002772 ↗
17. 10.1002/jbm.a.3087410.1002/jbm.a.30874 ↗
18. 10.1093/glycob/cwg08210.1093/glycob/cwg082 ↗
19. 10.1006/bbrc.1997.694510.1006/bbrc.1997.6945 ↗
20. Wound repair, keratinocyte activation and integrin modulation10.1242/jcs.101.1.1 ↗
21. Structurally different RGTAs modulate collagen‐type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor‐2 or transforming growth factor‐β110.1096/fj.03-1126fje ↗
22. 10.1096/fj.00-0756com10.1096/fj.00-0756com ↗
23. 10.1016/S0305-4179(02)00193-610.1016/S0305-4179(02)00193-6 ↗
24. 10.1016/0016-5085(92)90314-O10.1016/0016-5085(92)90314-O ↗
25. 10.1172/JCI1366210.1172/JCI13662 ↗
26. 10.1096/fj.04-1970com10.1096/fj.04-1970com ↗
27. 10.1074/jbc.M50449220010.1074/jbc.M504492200 ↗
28. 10.1002/jbm.a.3088010.1002/jbm.a.30880 ↗
29. Extravasation: A dreaded complication of chemotherapy10.1093/annonc/mdg744 ↗
30. Treatment of chemotherapy extravasation: current status